Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score
- PMID: 2256738
- PMCID: PMC1004262
- DOI: 10.1136/ard.49.11.916
Judging disease activity in clinical practice in rheumatoid arthritis: first step in the development of a disease activity score
Abstract
An investigation of clinical and laboratory variables which might form the basis for judging disease activity in clinical practice was made by six rheumatologists in a prospective study of up to three years' duration of 113 patients with early rheumatoid arthritis. Decisions to start treatment with slow acting antirheumatic drugs were equated with moments of high disease activity. If treatment with slow acting antirheumatic drugs was not started or if the slow acting antirheumatic drug remained unchanged for at least one year or if treatment was stopped because of disease remission, this was equated with periods of low disease activity. Two groups, one with high and one with low disease activity according to the above criteria, were formed. Factor analysis was performed to enable easy handling of the large number of clinical and laboratory variables without loss of information; this resulted in five factors. Next, discriminant analysis was done to determine to what extent each factor contributed to discrimination between the two groups of differing disease activity. Finally, a multiple regression analysis was carried out to determine which laboratory and clinical variables underlie the factors of the discriminant function, resulting in a 'disease activity score'. This score consisted of the following variables: Ritchie index, swollen joints, erythrocyte sedimentation rate, and general health, in declining importance. The rheumatologists' decisions to prescribe slow acting antirheumatic drugs, or not, were mainly based on articular symptoms.
Similar articles
-
Development of a disease activity score based on judgment in clinical practice by rheumatologists.J Rheumatol. 1993 Mar;20(3):579-81. J Rheumatol. 1993. PMID: 8478878
-
Prognostic factors for remission in early rheumatoid arthritis: a multiparameter prospective study.Ann Rheum Dis. 2004 Jun;63(6):675-80. doi: 10.1136/ard.2003.010611. Ann Rheum Dis. 2004. PMID: 15140774 Free PMC article.
-
Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study).PLoS One. 2015 Dec 23;10(12):e0145468. doi: 10.1371/journal.pone.0145468. eCollection 2015. PLoS One. 2015. PMID: 26698858 Free PMC article. Clinical Trial.
-
An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists.Clin Ther. 2009 Aug;31(8):1737-46. doi: 10.1016/j.clinthera.2009.08.009. Clin Ther. 2009. PMID: 19808132 Review.
-
Databases of patients with early rheumatoid arthritis in the USA.Clin Exp Rheumatol. 2003 Sep-Oct;21(5 Suppl 31):S146-53. Clin Exp Rheumatol. 2003. PMID: 14969067 Review.
Cited by
-
Baseline bony erosions and time-averaged DAS28 predict discontinuation of TNF inhibitors in rheumatoid arthritis.Sci Rep. 2022 Nov 19;12(1):19951. doi: 10.1038/s41598-022-24027-6. Sci Rep. 2022. PMID: 36402804 Free PMC article.
-
Asymmetric dimethylarginine and arterial stiffness in patients with rheumatoid arthritis: A case-control study.J Int Med Res. 2016 Sep;44(1 suppl):76-80. doi: 10.1177/0300060515593255. J Int Med Res. 2016. PMID: 27683145 Free PMC article.
-
Rituximab and concomitant leflunomide for the treatment of rheumatoid arthritis.Rheumatol Int. 2010 Mar;30(5):709-12. doi: 10.1007/s00296-009-1302-z. Epub 2009 Dec 12. Rheumatol Int. 2010. PMID: 20012622
-
Antineutrophil cytoplasmic antibodies in Bulgarian patients with rheumatoid arthritis: characterization and clinical associations.Rheumatol Int. 2005 Dec;26(2):107-14. doi: 10.1007/s00296-004-0517-2. Epub 2004 Nov 11. Rheumatol Int. 2005. PMID: 16341903
-
Raised human cartilage glycoprotein-39 plasma levels in patients with rheumatoid arthritis and other inflammatory conditions.Ann Rheum Dis. 2000 Jul;59(7):544-8. doi: 10.1136/ard.59.7.544. Ann Rheum Dis. 2000. PMID: 10873965 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical